Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells

International Journal of Hematology

Volumn 99, Issue 6, 2014, Pages 726-736

  Kikuchi, Jiro ^a   Koyama, Daisuke ^a   Mukai, Harumi Y ^b   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Janssen Pharmaceutical KK   (Japan)

Author keywords

Bone marrow microenvironment; Bortezomib; Drug combination; Isobologram

Indexed keywords

BORTEZOMIB; CASPASE 3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBRONECTIN; LENALIDOMIDE; MELPHALAN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG COMBINATION; PYRAZINE DERIVATIVE;

ARTICLE; BONE MARROW CELL; BONE MARROW STROMAL CELL; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; STROMA; STROMA CELL; U266 CELL LINE; UPREGULATION; BONE MARROW; CELL CULTURE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FIBRONECTINS; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; PYRAZINES; TUMOR MICROENVIRONMENT;

EID: 84905365683     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1573-3     Document Type: Article

References (54)

1. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947-59.
2. Suzuki K. Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol. 2013;43:116-24.
3. Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitination and degradation. Nat Rev Mol Cell Biol. 2011;12:605-20.
4. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochem Biophys Acta. 2012;1825:64-76.
5. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Oezzella F, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009;15:57-66.
6. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406-17.
7. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JK, Zucker SN, et al. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood. 2012;119:1450-8.
8. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006;12:591-9.
9. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231-42.
10. Srypayap P, Nagai T, Hatano K, Kikuchi J, Furukawa Y, Ozawa K. Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells. Acta Haematol. 2014;132:1-4.
11. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang K-D, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. 2010;17:427-42.
12. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175-82.
13. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai Y-T, et al. The selective adhesion molecule inhibitor Natalizmab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011;155:438-48.
14. Miguel JS, Shlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448-55.
15. Kumar S, Finn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375-82.
16. Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013;31:247-55.
17. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679-86.
18. Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M, et al. Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study. Int J Hematol. 2013;98:179-85.
19. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-98.
20. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94:334-43.
21. Drexler HG, Matsuo Y, MacLeod RA. Persistent use of false myeloma cell lines. Hum Cell. 2003;16:101-5.
22. Mori T, Kiyono T, Imabayashi H, Takeda Y, Tsuchiya K, Miyoshi S, et al. Combination of hTERT and bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic potential. Mol Cell Biol. 2005;25:5183-95.
23. Kawada H, Ando K, Tsuji T, Shimaoka Y, Nakamura Y, Chargui J, et al. Rapid ex vivo expansion of human umbilical cord blood hematopoietic progenitors using a novel culture system. Exp Hematol. 1999;27:904-15.
24. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by up-regulating CD20 expression on lymphoma cells. Leukemia. 2010;24:1760-8.
25. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85-93.
26. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999-2007.
27. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia. 2007;21:1005-14.
28. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-6.
29. Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem. 2013;288:25593-602.
30. Kikuchi J, Shibayama N, Yamada S, Wada T, Nobuyoshi M, Izumi T, et al. Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. PLoS One. 2013;8:e60649.
31. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010;24:1506-12.
32. Nakamura S, Miki H, Kido S, Nakano A, Hiasa M, Oda A, et al. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. Int J Hematol. 2013;98:66-73.
33. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International myeloma working group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716-30.
34. Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int J Hematol. 2013;97:333-44.
35. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23:1337-41.
36. Fernández de Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27: 780-91.
37. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, Rabinowitz I. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol. 2010;85:733-4.
38. D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23:1499-502.
39. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis M-C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014;89:145-50.
40. Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JF, Jacobson PA. Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatr Blood Cancer. 2012;58:708-14.
41. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood. 2002;100:224-9.
42. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res. 2007;67:7395-405.
43. Varde DN, Oliveria V, Mathews L, Wang X, Villagra A, Boulware D, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009;69:9367-75.
44. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, et al. Bortezomib induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118:6368-79.
45. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai Y-T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-80.
46. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12:104-20.
47. Popat R, Maharaj L, Oakervee H, Cavenagh J, Joel S. Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma. Br J Haematol. 2013;160:111-4.
48. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16:5079-86.
49. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res. 2003;113:88-95.
50. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007;21:524-8.
51. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22-32.
52. Schortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32:4191-202.
53. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345-50.
54. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326-35.